Lonvoguran ziclumeran (lonvo-z)

Name: Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Pharmacokinetics
Published: 2026-09-14T15:39:06-04:00

Hereditary angioedema

Also known as NTLA-2002

Manufacturer: Intellia Therapeutics
Regulatory submission: Rolling BLA initiated April 2026 and accepted September 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacokinetics

2 evidence topics · 1 source

Pharmacokinetics: lipid nanoparticle component exposure and clearance

“The concentration-time profile of LP01, a representative component of NTLA-2002, demonstrates dose-dependent exposure and rapid clearance” (opens the source at this quote in a new tab)

LP01 plasma half-life

“Estimated mean t1/2 range, 16.8 – 21.3 h.” (opens the source at this quote in a new tab)